Transgene (TNG)

Business description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Waiting for the deal

Update | Pharmaceutical & healthcare | 27/03/2015

Transgene is still in discussions with potential partners for the licensing of TG4010. We believe a deal is reliant on evidence that TG4010 acts synergistically with immune checkpoint inhibitors and mature data from the Phase IIb part of the TIME study in non-small cell lung cancer (NSCLC), showing a significant long-term overall survival benefit. At the same time, Transgene aims to start a number of trials this year, including a Phase III study with Pexa-Vec with its partners. We value Transgene at €464m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€193.7m
Last close€3.120
High / Low (52 weeks)€3.6 / €2.5
Stock market listingEU
Forecast net debt (€m)29.4
Forecast gearing ratio (%)164
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual3.116.014.3
Relative *8.216.64.7

* % Relative to local index

Company news

Transgene

Thu, 08 Jun 2017 16:02:29 GMT

Transgene

Thu, 12 Nov 2015 07:00:34 GMT

Transgene

Tue, 20 Feb 2018 00:11:13 GMT

Transgene

Wed, 03 Feb 2016 16:52:30 GMT

Transgene

Tue, 13 Feb 2018 18:56:15 GMT